YU-WEI ZENG1, MING ZHANG2, DAN-DAN HUANG3, YONG-HONG ZHENG
1The first affiliated hospital of chongqing medical university, Chongqin,China - 2Department of Cardiology, The Second Affiliated Hospital, Xi’an Medical University, Xi’an, Shanxi, China - 3Preeclinical School of North Sichuan Medical College
Objective: To investigate the clinical efficacy of combined medication of bisoprolol and irbesartan on chronic congestive heart failure.
Methods: A total of 98 patients with chronic congestive heart failure who were admitted to this hospital for treatment between June 2015 and May 2017 were selected as the subjects, and randomly divided into two groups, i.e. the control group and the observa- tion group. For patients in the control group, they underwent regular treatment, while those in the observation group, they addition- ally received the combined medication of bisoprolol and irbesartan. Then the ameliorations in heart functions were compared between two groups through changes in measurements of blood pressure, heart fate, left ventricular ejection fraction (LVEF), end- systolic and -diastolic volumes.
Results: After treatment, indicators of patients in two groups were all ameliorated significantly in these two groups, while the amelioration in the observation group was much better than that in the control group (p<0.05). In terms of the effectiveness, the effective rate in the observation was as high as 93.9%, significantly higher than 77.6% in the control group (p<0.05).
Conclusion: Combined medication of bisoprolol and irbesartan manifest significant effectiveness in treatment of chronic con- gestive heart failure through ameliorating the indicators of heart function. In addition, this strategy can increase the effectiveness of treatment, which is conducive to the health of patients, and deserves to be promoted in clinical practice.
bisoprolol, irbesartan, chronic congestive heart failure, efficacy